MAP - Market Access Podcast

In the newest episode of MAP - the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada's market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape. Whether you're dealing with drugs or me...

What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special guest, Glib Kutepov, CEO and founder of Modulate, shares his expertise.  Glib uncovers the potential of generative AI and neural networks in revolutionizing market access strategies and highlights the challenges and solutions around data privac...

Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles...

In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services. Join us as A...

Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of network...

In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the US market. Whether you're in medtech, pharma, biotech, or health tech, understanding the US healthcare landscape is key to your product's success. Join us as Dr. Stefan Walzer and Paul-Lukas Hoffschmidt, CEO of Alpha Sophia ( www.alphasophia.com ), sh...

Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health economist and founder of Mars Market Access & Pricing Strategy, engages with Dr. Benoit Salaun, a seasoned expert in French healthcare reimbursement. They unravel: The nuances of the French healthcare system The essentials of medical device reimburs...

In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access. Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate. In this episo...

Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape. 🇪🇸 Join us as Sergio Gil , a seasoned veteran with over three decades in the medical device industry, shares his invaluab...

We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare? Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time, Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this? Dr. Stefan Walze...

We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff.  Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving m...

🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market! In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage...

🎙️ Exciting Podcast Episode Is Here! 🎙️ In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access! 🎯 What's Happening? Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with t...

Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023! 🚀 Dive Deep into the Core of Pharmaceutical Reforms! Matthias...

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi   Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“.&nbsp...

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings: - What are the differences between Clinical Develop...

🎧 Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi    🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems...  💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisa...

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in...

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi   New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-commi...

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved? In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company st...

In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships? The #marketaccess veterans Dr. Stefan Walzer and Dr. J...

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works.  The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore. With Medicare the government directly funds pharmaceuticals for 65+ years old population. With Medicaid the government fund low incom...

The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world! In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs a...

Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication. Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in ar...

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments.  One of these advocates is Dr. Ka...